secwatch.observer — SEC 8-K summary
======================================

Issuer:     RELMADA THERAPEUTICS, INC. (RLMD)
CIK:        0001553643
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001213900-23-038577
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relmada Therapeutics reports Q1 2023 net loss of $26.3M; provides REL-1017 trial update
--------------------------------------------------------------------------------

- Net loss of $26.3M ($0.87 per share) vs $39.7M ($1.40) in Q1 2022.
- R&D expense fell to $15.9M from $25.0M, driven by completion of RELIANCE I and III studies.
- Cash, cash equivalents, and short-term investments of $132.4M as of March 31, 2023.
- Enrollment ongoing in Phase 3 Study 302 (REL-1017 for MDD); completion expected H1 2024.
- New Phase 3 Study 304 to start mid-2023 with ~300 patients; completion anticipated H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023038577/0001213900-23-038577-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1553643/000121390023038577/ea178401-8k_relmada.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-038577

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer